PDF herunterladen
Thromb Haemost 1976; 35(03): 643-650
DOI: 10.1055/s-0038-1647963
Original Article
Schattauer GmbH

Plasmin inactivation in Plasma

E. M Haselager
1   Department of Internal Medicine, University Hospital Wilhelmina Gasthuis, Amsterdam, The Netherlands
,
Th. M Goote
1   Department of Internal Medicine, University Hospital Wilhelmina Gasthuis, Amsterdam, The Netherlands
,
J Vreeken
1   Department of Internal Medicine, University Hospital Wilhelmina Gasthuis, Amsterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 06. Oktober 1975

Accepted 12. Dezember 1975

Publikationsdatum:
24. Juli 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Inhibition and inactivation of plasmin is ascribed to α2-macroglobulin, α1-antitrypsin and c1-esterase inhibitor. In an “overall” inactivation test of plasmin in plasma, which comes perhaps closest to rapid inactivation of plasmin in the circulating blood, we only found a correlation between the immunological concentration of α2-macroglobulin and the plasmin-inac-tivating capacity of the plasma, but no correlation with the immunological concentration of the other inhibitors mentioned. Therefore, α2-macroglobulin seems to be the most important plasmin inhibitor in relation to thrombosis.

 

  • References

  • 1 Aberg M, Nilsson I. M, Hedner U. 1973; Antithrombin III after operation. Lancet II: 1337.
    PubMedGoogle Scholar
  • 2 Amris C. J, Larsen V, Mogensen B, Storm O. 1963; Infusion of porcine plasmin in man. Scandinavian Journal of Clinical and Laboratory, Investigation 15: 179.
    CrossrefPubMedGoogle Scholar
  • 3 Barrett A. J, Starkey P. M. 1973; The interaction of α2-macroglobulin with proteinases. Biochemical Journal 133: 709.
    CrossrefPubMedGoogle Scholar
  • 4 Biggs R, Denson K. W. E, Akman N, Borrett R, Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haematology 19: 287.
    PubMedGoogle Scholar
  • 5 Blatrix C, Amouch P, Dronet J, Steinbuch M. 1973 Study on the plasmatic elimination of the α2-M proteinase complexes. Pathologie – Biologie. 20. Suppl. II.
    PubMedGoogle Scholar
  • 6 Boyde T. R. C, Pryme E. F. 1968; α2-microglobulin binding of trypsin, chymotrypsin/papain, and cationic asparate aminotransferase. Clinica Chimica Acta 21: 9.
    CrossrefPubMedGoogle Scholar
  • 7 Collen D, de Cock F, Verstraete M. 1975; Immunochemical distinction between antiplasmin and α1antitrypsin. Thrombosis Research 7: 245.
    CrossrefPubMedGoogle Scholar
  • 8 Colman R. W. 1974; Formation of human kinin. New England Journal of Medicine 291: 509.
    CrossrefPubMedGoogle Scholar
  • 9 Donati M. B, Vandenberghe K, Molla A, de Roo M, Verstraete M. 1973; Postoperative antithrombin III. Lancet I: 726.
    PubMedGoogle Scholar
  • 10 Ganrot P. O. 1966; Determination of α2-macroglobulin as trypsinprotein esterase. Clinica Chimica Acta 14: 493.
    CrossrefPubMedGoogle Scholar
  • 11 Ganrot P. O, Schersten B. 1967; Serum α2-macroglobulin concentration and its variation with age and sex. Clinica Chimica Acta 15: 113.
    CrossrefPubMedGoogle Scholar
  • 12 Ganrot P. O. 1967; Inhibition of plasmin activity by α2-macroglobulin. Clinica Chimica Acta 16: 328.
    CrossrefPubMedGoogle Scholar
  • 13 Ganrot P. O, Nilehn J. E. 1967; Competition between plasmin and thrombin for α2-macroglobulin. Clinica Chimica Acta 17: 511.
    CrossrefPubMedGoogle Scholar
  • 14 Ganrot P. O. 1967; Interaction of plasmin and trypsin with α2-macroglobulin. Acta Chemia Scan-dinavica 21: 602.
    PubMedGoogle Scholar
  • 15 Harpel P. C. 1970; Human α2-macroglobulin. Journal of Experimental Medicine 132: 329.
    CrossrefPubMedGoogle Scholar
  • 16 Hedner U, Nilsson I. M. 1973; Antithrombin III in a clinical material. Thrombosis Research 3: 631.
    CrossrefPubMedGoogle Scholar
  • 17 Hedner U. 1974 Fibrinolytic inhibitors. Supplementum LIX ad Thrombosis et Diathesis Haemorrhagica. 281.
    PubMedGoogle Scholar
  • 18 Laurell C. B. 1966; Quantitative estimation of proteins by electrophoresis in agarase gel containing antibodies. Analytical Biochemistry 15: 45.
    CrossrefPubMedGoogle Scholar
  • 19 Schreiber A. D, Kaplan A. P, Austen K. F. 1973; Plasmin inhibitors of the components of the fibrinolytic pathway in man. Journal of Clinical Investigation 52: 1394.
    CrossrefPubMedGoogle Scholar
  • 20 Stathakis N, Papyannis A. G, Gardikas C. D. 1973; Postoperative antithrombin III concentration. Lancet I: 430.
    PubMedGoogle Scholar
  • 21 Strengers Th, Asberg E. G. M. 1963; Een Screeningtest, gevolgd door een snelle kwantitatieve microbepaling van fibrinogeen in plasma. Nederlands Tijdschrift voor Geneeskunde 107: 2044.
    PubMedGoogle Scholar
  • 22 Yin E. T, Wessler S. 1970; Heparin-accelerated inhibition of activated factor X by its natural inhibitor. Biochemical Biophysical Acta 201: 387.
    PubMedGoogle Scholar
  • 23 Yin E. T, Wessler S, Stoll P. 1971; Biological properties of the naturally occurring plasma inhibitor to activated factor X. Journal of Biological Chemistry 246: 3703.
    PubMedGoogle Scholar